Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will announce $23.07 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Theravance Biopharma’s earnings, with estimates ranging from $16.00 million to $30.00 million. Theravance Biopharma posted sales of $26.15 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.8%. The business is expected to announce its next quarterly earnings results on Wednesday, July 29th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $110.15 million for the current financial year, with estimates ranging from $101.91 million to $125.00 million. For the next financial year, analysts anticipate that the company will post sales of $151.25 million, with estimates ranging from $100.38 million to $207.59 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.33). The business had revenue of $19.86 million during the quarter, compared to analysts’ expectations of $18.02 million.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP lifted its position in shares of Theravance Biopharma by 13.7% during the 1st quarter. Engineers Gate Manager LP now owns 40,621 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 4,886 shares during the last quarter. BlackRock Inc. lifted its position in shares of Theravance Biopharma by 129.3% during the 1st quarter. BlackRock Inc. now owns 8,780,790 shares of the biopharmaceutical company’s stock worth $202,923,000 after purchasing an additional 4,951,711 shares during the last quarter. State Street Corp lifted its position in shares of Theravance Biopharma by 10.0% during the 1st quarter. State Street Corp now owns 1,055,268 shares of the biopharmaceutical company’s stock worth $24,387,000 after purchasing an additional 95,704 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Theravance Biopharma by 17.6% during the 1st quarter. Geode Capital Management LLC now owns 719,072 shares of the biopharmaceutical company’s stock worth $16,617,000 after purchasing an additional 107,724 shares during the last quarter. Finally, Arizona State Retirement System acquired a new position in shares of Theravance Biopharma during the 1st quarter worth about $231,000. 88.47% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ TBPH opened at $19.94 on Friday. The business’s 50-day moving average price is $24.22 and its two-hundred day moving average price is $25.28. Theravance Biopharma has a one year low of $15.72 and a one year high of $31.54. The company has a market capitalization of $1.26 billion, a P/E ratio of -4.59 and a beta of 1.43.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Story: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.